Panitumumab - Biologic Drug Details

Summary for panitumumab

Tradenames:	1
High Confidence Patents:	2
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for panitumumab

Recent Clinical Trials for panitumumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
M.D. Anderson Cancer Center	EARLY_PHASE1
SWOG Cancer Research Network	PHASE3
National Cancer Institute (NCI)	PHASE3

See all panitumumab clinical trials

Pharmacology for panitumumab

Mechanism of Action	HER1 Antagonists
Established Pharmacologic Class	Epidermal Growth Factor Receptor Antagonist
Chemical Structure	Antibodies, Monoclonal

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for panitumumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for panitumumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	VECTIBIX	panitumumab	Injection	125147	10,034,948	2037-09-08	DrugPatentWatch analysis and company disclosures
Amgen Inc.	VECTIBIX	panitumumab	Injection	125147	10,213,485	2035-08-27	DrugPatentWatch analysis and company disclosures
Amgen Inc.	VECTIBIX	panitumumab	Injection	125147	10,646,554	2037-08-23	DrugPatentWatch analysis and company disclosures
Amgen Inc.	VECTIBIX	panitumumab	Injection	125147	11,040,094	2036-07-01	DrugPatentWatch analysis and company disclosures
Amgen Inc.	VECTIBIX	panitumumab	Injection	125147	11,357,808	2040-11-11	DrugPatentWatch analysis and company disclosures
Amgen Inc.	VECTIBIX	panitumumab	Injection	125147	6,235,883	2017-05-05	DrugPatentWatch analysis and company disclosures
Amgen Inc.	VECTIBIX	panitumumab	Injection	125147	7,105,152	2023-09-12	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for panitumumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	VECTIBIX	panitumumab	Injection	125147	10,016,338	2036-12-20	Patent claims search
Amgen Inc.	VECTIBIX	panitumumab	Injection	125147	10,016,440	2031-04-21	Patent claims search
Amgen Inc.	VECTIBIX	panitumumab	Injection	125147	10,022,451	2035-05-11	Patent claims search
Amgen Inc.	VECTIBIX	panitumumab	Injection	125147	10,023,917	2035-12-03	Patent claims search
Amgen Inc.	VECTIBIX	panitumumab	Injection	125147	10,030,270	2032-06-14	Patent claims search
Amgen Inc.	VECTIBIX	panitumumab	Injection	125147	10,040,857	2035-11-20	Patent claims search
Amgen Inc.	VECTIBIX	panitumumab	Injection	125147	10,041,934	2036-06-24	Patent claims search

International Patents for panitumumab

Country	Patent Number	Estimated Expiration
South Africa	201107774
Mexico	382443
Cyprus	2007032
Australia	2011252851
Taiwan	201206463
Mexico	2013000321
European Patent Office	4349868

Supplementary Protection Certificates for panitumumab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
132014902246023	Italy		PRODUCT NAME: FIBRINOGENO/TROMBINA/CELLULOSA OSSIDATA RIGENERATA(EVARREST); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/868, 20140925
4/2008	Austria		PRODUCT NAME: PANITUMUMAB; REGISTRATION NO/DATE: EU/1/07/423/001- EU/1/07/423/003 20071203
2007C/071	Belgium		PRODUCT NAME: PAPILLOMAVIRUS (HUMAIN TYPES 16,18); AUTHORISATION NUMBER AND DATE: EU/1/07/419/001 20070924
08C0006	France		PRODUCT NAME: PANITUMUMAB; REGISTRATION NO/DATE: EU/1/07/423/001 20071203
08C0022	France		PRODUCT NAME: PANITUMUMAB; REGISTRATION NO/DATE IN FRANCE: EU/1/07/423/001 DU 20071203; REGISTRATION NO/DATE AT EEC: EU/1/07/423/001 DU 20071203
305	Finland
C 2008 003	Romania		PRODUCT NAME: PANITUMUMAB; NATIONAL AUTHORISATION NUMBER: RO EU/1/07/423/001, RO EU/1/07/423/002, RO EU/1/07/423/003; DATE OF NATIONAL AUTHORISATION: 20071203; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/07/423/001, EU/1/07/423/002, EU/1/07/423/003; DATE OF FIRST AUTHORISATION IN EEA: 20071203

Market Dynamics and Financial Trajectory for Panitumumab

Last updated: February 13, 2026

What is Panitumumab and How Does It Fit Into Oncology?

Panitumumab is a fully human monoclonal antibody targeting epidermal growth factor receptor (EGFR). It primarily treats wild-type RAS metastatic colorectal cancer (mCRC). Approved by the FDA in 2006, it is marketed under the brand name Vectibix by Amgen.

What is the Current Market Size for Panitumumab?

As of 2022, the global oncology monoclonal antibody market was valued at approximately $140 billion, expected to grow at a compound annual growth rate (CAGR) of roughly 6% through 2027. Panitumumab accounts for a small but distinct segment within anti-EGFR therapies for colorectal cancer (CRC).

• Estimated Panitumumab-specific revenue (2022): $600–$700 million worldwide.
• Market share in CRC biologics: Approximately 4-6%, varying across regions.
• Regional dynamics:
  • North America: 50-60% of total sales.
  • Europe: 30-35%.
  • Asia-Pacific: 8-10% but growing due to expanding oncology access.

How Does Competition Affect Panitumumab’s Market Position?

Panitumumab competes with cetuximab, another EGFR inhibitor, for first-line and refractory CRC. From 2020 onward, increased efficacy data, dosing convenience, and side effect profiles have influenced market share.

• Key competitors:
  • Cetuximab (Erbitux, Merck): leads the market with ~$2 billion global sales.
  • Other emerging therapies include KRAS/NRAS inhibitors and immunotherapies, depending on molecular profile.
• Physician preferences: Favor cetuximab for its longer history, although panitumumab's fully human composition aims to reduce infusion reactions.

What are the Main Factors Driving Market Growth?

1. Expanded indications: Panitumumab’s approvals for adjuvant and refractory CRC expand its market.
2. Biomarker-driven therapy: Companion diagnostics for RAS wild-type status enhance patient selection, increasing drug efficacy.
3. Rising CRC incidence: The WHO projects CRC to become the third most diagnosed cancer globally, with 1.9 million new cases annually.
4. Innovation and pipeline: Ongoing trials assess panitumumab in combination with immunotherapies and novel agents for other solid tumors.

What Are the Key Regulatory and Pricing Policies Impacting Revenue?

• Pricing: List prices in the US range from $12,000 to $15,000 per treatment cycle (every two weeks). Insurance reimbursement varies by region and policy.
• Market Access: Payers increasingly demand evidence of cost-effectiveness; pharmacoeconomic models cite incremental cost-effectiveness ratios (ICERs) around $100,000–$150,000 per quality-adjusted life year (QALY).
• Regulations: European Medicines Agency (EMA) approval aligns with FDA, but access varies due to country-specific pricing controls.

How Will Patent and Patent Expiry Impact Revenues?

• Patent status:
  • Original composition patent expired in 2019 in the US.
  • Secondary patents and exclusivity rights extend until 2025–2027.
• Biosimilar market entry:
  • Several biosimilars for EGFR inhibitors are under development or approved in select markets.
  • In Europe, biosimilar cetuximab launched in 2018, undercutting originator prices by 20-30%.
  • Biosimilars for panitumumab are expected around 2024, likely reducing revenue by 15–25%, based on biosimilar pricing trends.

What Financial Outlook Is Predicted for Panitumumab?

• Revenue projections:
  • 2023–2025: Maintain stable sales, 3-5% annual growth driven by expanded indications in refractory CRC.
  • Post-2025: Potential decline due to biosimilar competition, with estimates suggesting a 20-25% reduction in US and European markets over five years.
• R&D pipeline investments:
  • Amgen invests in combination studies with immunotherapies and novel payloads to extend lifecycle.
  • Clinical trials include head-to-head comparisons against other monoclonal antibodies in colorectal and lung cancers.

Summarized Financial Metrics

Metric	2022	2023 (Projected)	2025 (Projected)
Total Revenue	$650 million	$700 million	$600 million (post-biosimilar entry)
Market Share	~5% of biologic CRC market	Stabilizing or declining	Decline expected as biosimilars penetrate
Growth Rate	0-2%	3-5%	-5% to -10% (due to biosimilar impact)

---

Key Takeaways

• Panitumumab remains a niche but significant player in the CRC biologics sector.
• Market growth is driven by expanding indications and rising CRC prevalence but faces headwinds from biosimilars and competitor efficacy advances.
• Sales are projected to plateau or decline post-2025, contingent on biosimilar market penetration.
• Regulatory developments and payor policies influence revenue stability.
• Continued investment in combination therapies may provide revenue extension.

---

FAQs

Q1: How does panitumumab compare with cetuximab in efficacy?
Both target EGFR and are approved for RAS wild-type mCRC. Panitumumab may have marginally better tolerability due to its fully human structure but no definitive superiority in efficacy.

Q2: What is the impact of biosimilar development on panitumumab revenues?
Biosimilar availability typically reduces originator prices by 20–30%, forcing revenue declines estimated at 15–25% over five years post-entry.

Q3: Are there new indications for panitumumab beyond CRC?
Current trials are exploring combination use in non-small cell lung cancer and head and neck cancers, but no additional approvals have been granted yet.

Q4: How do payor policies influence panitumumab market access?
Cost-effectiveness assessments and negotiated pricing reduce reimbursement rates, especially in Europe. In the US, high list prices are offset by insurance and Medicare coverage but pressure payor budgets.

Q5: What are the prospects for panitumumab in the next decade?
Limited growth prospects after biosimilar entry unless new indications or combination therapies significantly expand its use.

---

References:

1. EvaluatePharma, 2022. "Oncology Monoclonal Antibodies Market Analysis."
2. Amgen, 2023. Vectibix product information.
3. WHO, 2022. "Global Incidence of Colorectal Cancer."
4. IQVIA, 2022. "Biologic Drug Sales Data."
5. U.S. Food and Drug Administration, 2006. "Panitumumab (Vectibix) Approval Announcement."